乳铁蛋白作为预防和治疗严重急性呼吸系统综合征冠状病毒2型感染的可能药物

IF 0.7 Q4 GEOSCIENCES, MULTIDISCIPLINARY
Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose
{"title":"乳铁蛋白作为预防和治疗严重急性呼吸系统综合征冠状病毒2型感染的可能药物","authors":"Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose","doi":"10.20965/jdr.2023.p0027","DOIUrl":null,"url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.","PeriodicalId":46831,"journal":{"name":"Journal of Disaster Research","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection\",\"authors\":\"Michiyo Kobayashi-Sakamoto, T. Maeda, J. Yusa, H. Tani, Y. Kato, K. Hirose\",\"doi\":\"10.20965/jdr.2023.p0027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.\",\"PeriodicalId\":46831,\"journal\":{\"name\":\"Journal of Disaster Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Disaster Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20965/jdr.2023.p0027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GEOSCIENCES, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Disaster Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20965/jdr.2023.p0027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GEOSCIENCES, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 1

摘要

严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)是2019年新型冠状病毒病(新冠肺炎)的病原体,该病是全球非典型肺炎的主要病因。老年人和患有心血管和肺部疾病等潜在疾病的人出现严重症状的风险很高,死亡率也很高。因此,迫切需要开发额外的疫苗、有效的治疗方法和补充药物来控制这种感染。乳铁蛋白(LF)是一种天然存在的糖蛋白,对病毒和其他病原体具有生物活性。LF具有独特的免疫调节功能,对婴儿的免疫是必不可少的。它被认为有助于各代人的生物防御,而不仅仅是婴儿。LF通过与糖胺聚糖的离子结合和/或与病毒结构的特异性结合来抑制病毒与宿主细胞表面的粘附。纯化LF具有成本效益,可作为膳食补充剂口服。在这里,我们回顾了LF对常见病毒感染的保护作用的研究。基于这篇综述,我们提出LF可以成为新冠肺炎疾病的一种可能的预防或治疗剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of novel coronavirus disease 2019 (COVID-19), a major cause of atypical pneumonia worldwide. Elderly individuals and those with underlying illnesses, such as cardiovascular and pulmonary diseases, are at a high risk of experiencing severe symptoms and have high mortality rates. There is therefore a major need to develop additional vaccines, effective treatments, and complementary drugs to control this infection. Lactoferrin (LF), a naturally-occurring glycoprotein, is bioactive against viruses and other pathogens. LF has a unique immunomodulatory function and is indispensable for immunity in infants. It is thought to contribute to biological defense in individuals across all generations, not only infants. LF inhibits viral adhesion to host cell surfaces through ionic binding to glycosaminoglycans and/or specific binding to viral structures. Purified LF is cost-effective and orally available as a dietary supplement. Here, we review studies on the protective role of LF against common viral infections. Based on this review, we propose that LF can be a possible prophylactic or therapeutic agent for COVID-19 disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Disaster Research
Journal of Disaster Research GEOSCIENCES, MULTIDISCIPLINARY-
CiteScore
1.60
自引率
37.50%
发文量
113
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信